Promoter activation by CII, a potent transcriptional activator from bacteriophage 186.

J Biol Chem

Department of Biochemistry, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia 5005, Australia. Electronic address:

Published: November 2014

The lysogeny promoting protein CII from bacteriophage 186 is a potent transcriptional activator, capable of mediating at least a 400-fold increase in transcription over basal activity. Despite being functionally similar to its counterpart in phage λ, it shows no homology at the level of protein sequence and does not belong to any known family of transcriptional activators. It also has the unusual property of binding DNA half-sites that are separated by 20 base pairs, center to center. Here we investigate the structural and functional properties of CII using a combination of genetics, in vitro assays, and mutational analysis. We find that 186 CII possesses two functional domains, with an independent activation epitope in each. 186 CII owes its potent activity to activation mechanisms that are dependent on both the σ(70) and α C-terminal domain (αCTD) components of RNA polymerase, contacting different functional domains. We also present evidence that like λ CII, 186 CII is proteolytically degraded in vivo, but unlike λ CII, 186 CII proteolysis results in a specific, transcriptionally inactive, degradation product with altered self-association properties.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231686PMC
http://dx.doi.org/10.1074/jbc.M114.608026DOI Listing

Publication Analysis

Top Keywords

186 cii
16
cii
9
potent transcriptional
8
transcriptional activator
8
bacteriophage 186
8
functional domains
8
cii 186
8
0
6
promoter activation
4
activation cii
4

Similar Publications

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.

Cancer Immunol Immunother

September 2024

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Kaiyang Fifth Road, Guangzhou, 510555, People's Republic of China.

Background: The anti-PD-L1 antibody durvalumab has been approved for use in first-line advanced biliary duct cancer (ABC). So far, predictive biomarkers of efficacy are lacking.

Methods: ABC patients who underwent gemcitabine-based chemotherapy with or without durvalumab were retrospectively enrolled, and their baseline clinical pathological indices were retrieved from medical records.

View Article and Find Full Text PDF

Previous studies have suggested a negative impact of steroids on the efficacy of immune checkpoint inhibitors (ICI), but how this effect is modulated by the dosage and time of administration is yet to be clarified. We have performed a retrospective analysis of 475 patients with advanced solid tumors treated with ICI as monotherapy from 2015 to 2022. Data regarding immune-related adverse events (irAEs) and clinical outcomes were collected.

View Article and Find Full Text PDF

Plague is an endemic infectious disease caused by . In this study, we isolated fourteen phages with similar sequence arrangements to phage 186; these phages exhibited different lytic abilities in Enterobacteriaceae strains. To illustrate the phylogenetic relationships and evolutionary relationships between previously designated 186-type phages, we analysed the complete sequences and important genes of the phages, including whole-genome average nucleotide identity (ANI) and collinearity comparison, evolutionary analysis of four conserved structural genes (, , , and genes), and analysis of the regulatory genes (, and ) and integrase gene ().

View Article and Find Full Text PDF

Despite decades of research, little is known regarding physiologic temporal limits for initiation of lactation in pregnant non-lactating cattle the aim of this study was to compare the lactation performances in primiparous Holstein cows after a short gestation length (GL) or abortion to those after a normal GL. The data were collected using an automated data collection system. The 94 herds evaluated were located in Belgium, France, Italy, the Netherlands and Germany.

View Article and Find Full Text PDF
Article Synopsis
  • Helicobacter pylori eradication therapy might worsen gastroesophageal reflux disease, raising questions about its impact on Barrett's esophagus, but this study aimed to clarify this relationship.
  • A retrospective analysis of 340 patients showed that while reflux esophagitis cases increased after treatment, only 0.6% experienced elongation of Barrett's esophagus.
  • The findings suggest that eradication therapy does not significantly affect the presence or lengthening of Barrett's esophagus in patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!